Learn more about the exciting field of intratumoral immunotherapy and OncoSec’s role as a key leader in this emerging space.
Watch the Video
OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer
OncoSec to Present at Eighth Annual BioNJ Partnering Conference
OncoSec Announces PISCES/KEYNOTE-695 Trial-in-Progress Poster Presentation at Upcoming ASCO 2018 Annual Meeting
OncoSec Provides Highlights from Research Reception at AACR Annual Meeting 2018
Our core technology platform continues to advance through clinical trials for various cancers.
The ImmunoPulse® platform is designed to boost the immune system to recognize and attack tumors.
OncoSec continues to establish relationships with industry leaders to further advance our research.
PDF | 2.0 MB
PDF | 1.0 MB